Startup · $63m raised
Every investor coverage indicates participated in a round Inflazome raised.
| Investor | Rounds | Invested |
|---|---|---|
| Forbion | Unnamed stage | - |
| Fountain Healthcare Partners | Unnamed stage | - |
| Longitude Capital | Unnamed stage | - |
| Novartis | Unnamed stage | - |
Companies Inflazome acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Thomas Jung | Chief Medical Officer | SmartCompany |
| Matt Cooper | Chief Executive | SmartCompany (Mon 17 Dec 2018), SmartCompany (Tue 4 Dec 2018) |
Stories naming Inflazome. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Sanofi is buying Vicebio for up to US$1.6 billion in the biggest-ever exit of Australian university IP, with UQ keeping equity; the article also recalls the Inflazome and Spinifex sales and Vicebio's Medicxi seed.
A year-end roundup of Australia's largest 2018 startup capital raises, covering Judo Capital, Deputy, Airwallex, Inflazome, SafetyCulture, Culture Amp, Canva, Havven, Athena, Ansarada and Data Republic, with investors and earlier rounds recalled.
Also Startup Daily·SmartCompany·Startup Daily·Techboard·SmartCompany·SmartCompany·SmartCompany·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Techboard·Techboard·SmartCompany·Startup Daily·SmartCompany·SmartCompany·Forbes Australia·Crunchbase News·Wholesale Investor
Queensland biotech firm Inflazome has secured a large funding round led by Forbian to advance its anti-inflammatory drug candidates into clinical trials, and has hired a chief medical officer to lead that development.
Also SmartCompany